Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Klein

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentGregory Klein, Gil D Rabinovici, Henrik Zetterberg, et al.
Alzheimer'S Research & Therapy|November 28, 2024
Head-to-head comparison of tau PET tracers [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohortMatteo Tonietto, Oscar Sotolongo-Grau, Núria Roé-Vellvé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 22, 2022
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid QuantificationAnne M Smith, Nancy A Obuchowski, Norman L Foster, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2026
Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's diseaseDavid López-Martos, Raffaele Cacciaglia, Marc Suárez-Calvet, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learningLinda Karlsson, Olof Strandberg, Ruben Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissueAnnalise Schweickart, Richa Batra, Kevin Huynh, et al.
Neurobiology of Aging|June 26, 2026
Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individualsDavid López-Martos, Marc Suárez-Calvet, Gemma Salvadó, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2018
Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup>C-RO-963, <sup>11</sup>C-RO-643, and <sup>18</sup>F-RO-948, in Healthy Controls and in Alzheimer SubjectsDean F Wong, Robert A Comley, Hiroto Kuwabara, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentGregory Klein, Gil D Rabinovici, Henrik Zetterberg, et al.
Alzheimer'S Research & Therapy|November 28, 2024
Head-to-head comparison of tau PET tracers [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohortMatteo Tonietto, Oscar Sotolongo-Grau, Núria Roé-Vellvé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 22, 2022
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid QuantificationAnne M Smith, Nancy A Obuchowski, Norman L Foster, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2026
Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's diseaseDavid López-Martos, Raffaele Cacciaglia, Marc Suárez-Calvet, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learningLinda Karlsson, Olof Strandberg, Ruben Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissueAnnalise Schweickart, Richa Batra, Kevin Huynh, et al.
Neurobiology of Aging|June 26, 2026
Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individualsDavid López-Martos, Marc Suárez-Calvet, Gemma Salvadó, et al.
The New England Journal of Medicine|November 15, 2023
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's DiseaseRandall J Bateman, Janice Smith, Michael C Donohue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2018
Characterization of 3 Novel Tau Radiopharmaceuticals, <sup>11</sup>C-RO-963, <sup>11</sup>C-RO-643, and <sup>18</sup>F-RO-948, in Healthy Controls and in Alzheimer SubjectsDean F Wong, Robert A Comley, Hiroto Kuwabara, et al.
Pageof 7